Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum elongation factor 2 (PfeEF2) is an essential enzyme that catalyzes the GTP-dependent translocation of the ribosome along messenger RNA, a critical step in protein synthesis. PfeEF2 plays a central role in the parasite's cytoplasmic translation machinery and is conserved among eukaryotes. It has been validated as a druggable target for antimalarial therapy; inhibitors such as DDD107498 disrupt parasite protein synthesis and kill multiple life cycle stages, supporting its use for both treatment and transmission blocking. Selectivity versus the host eEF2 is a design priority due to sequence homology, but successful selective inhibition demonstrates its value as a target for antimalarial drug development[3][4][6].
Inhibition of protein synthesis via inhibition of GTP-dependent ribosomal translocation[3][4]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum elongation factor 2 (PfeEF2).